Name: Recombinant Human B-lymphocyte antigen CD20 (MS4A1)-VLPs (Active)
Brand: CUSABIO
SKU: CSB-MP015007HU

Product Details

Purity

Greater than 90% as determined by SEC-HPLC.

Endotoxin

Less than 1.0 EU/ug as determined by LAL method.

Activity

Measured by its binding ability in a functional ELISA. Immobilized human CD20 at 2 μg/mL can bind Anti-CD20 recombinant antibody (CSB-RA015007A1HU), the EC₅₀ is 3.243-7.085 ng/mL.

Target Names

MS4A1

Uniprot No.

P11836

Research Area

Cancer

Alternative Names

MS4A1; CD20; B-lymphocyte antigen CD20; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1; CD antigen CD20

Molecular Characterization

Species

Homo sapiens (Human)

Source

Mammalian cell

Expression Region

1-297aa

Target Protein Sequence

MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP

Mol. Weight

34.4 kDa

Protein Length

Full Length

Tag Info

C-terminal 10xHis-tagged (This tag can be tested only under denaturing conditions)

Form

Lyophilized powder
Note: We will default ship it in lyophilized form with normal bule ice packs. However, if you request to ship in liquid form, it needs to be shipped with dry ice, please communicate with us in advance and extra fees for dry ice and dry ice box will be charged.

Buffer

Lyophilized from a 0.2 μm sterile filtered PBS, 6% Trehalose, pH 7.4

Troubleshooting and FAQs

Protein FAQs

Storage Condition

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shelf Life

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Lead Time

Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Datasheet & COA

Please contact us to get it.

Description

This recombinant human CD20 (MS4A1) protein is produced as a virus-like particle (VLP) in mammalian cells, encompassing the full-length (amino acids 1-297) with a C-terminal 10×His tag for enhanced purification and detection. The VLP formulation mimics native membrane presentation while maintaining excellent purity (>90% by SDS-PAGE) and low endotoxin levels (<1.0 EU/μg, LAL method).

Functional analysis demonstrates that the recombinant MS4A1 protein specifically binds to the anti-CD20 recombinant antibody (CSB-RA015007A1HU) in ELISA format (EC₅₀: 3.243-7.085 ng/mL), validating its structural integrity and biological relevance. The VLP structure provides multiple CD20 epitopes in their native conformation, making this preparation particularly valuable for the development and evaluation of CD20-targeting therapeutics, vaccine research against B-cell malignancies, structural studies of antibody-CD20 interactions, and B-cell immunology research.

The mammalian expression system ensures proper post-translational modifications, while the lyophilized form offers convenient storage and handling. This MS4A1 VLP represents an advanced tool for cancer research, particularly in studies of B-cell lymphomas and therapeutic antibody development, combining the benefits of recombinant protein technology with native-like membrane presentation.

Human CD20 protein, also known as MS4A1, is a transmembrane protein predominantly expressed on B-lymphocytes. It has significant implications in both normal immune function and pathological conditions, particularly in hematological malignancies such as lymphomas. Structurally, CD20 is composed of four hydrophobic transmembrane domains, with both N- and C-termini located in the cytoplasm, which is critical for its role in cellular signaling and receptor organization on the B-cell surface [1][2][3].

CD20 functions primarily as a regulator of B-cell activation, influencing processes such as cell proliferation, differentiation, and immunoglobulin secretion. Unlike many surface proteins, CD20 does not have a known natural ligand, suggesting its function is primarily cell-intrinsic [3][4]. It has been identified as a calcium-permeable cation channel that plays a vital role in calcium signaling, essential for B-cell activation [5][6]. The involvement of CD20 in calcium mobilization indicates its crucial role in initial B-cell activation, which subsequently regulates various downstream signaling pathways essential for immune responses [4][7].

The presence of CD20 on B cells makes it an important target for therapeutic interventions, particularly in the form of monoclonal antibodies like rituximab. The binding of these antibodies to CD20 induces the death of B cells through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) [8][9]. These effects are particularly relevant in the context of treatments for B-cell malignancies, where anti-CD20 therapies have shown significant efficacy [10][11]. For instance, studies have shown that anti-CD20 antibodies can profoundly impact the clinical outcomes in B-cell neoplasms by depleting CD20-positive cells, leading to therapeutic remission in many patients [12][10].

Furthermore, CD20 expression is relatively restricted, absent in terminally differentiated plasma cells and expressed at various stages of B-cell development, including pre-B, immature, mature, and activated B cells [1][13]. This selective expression pattern makes CD20 a useful biomarker for identifying B-cell populations in clinical diagnostics and research settings. Understanding the functional implications of CD20's activity and its interaction with therapeutic antibodies continues to drive research aimed at improving outcomes in B-cell-related diseases [14].

References:
[1] T. Kuijpers, R. Bende, et al. Cd20 deficiency in humans results in impaired t cell–independent antibody responses. Journal of Clinical Investigation, vol. 120, no. 1, p. 214-222, 2010. https://doi.org/10.1172/jci40231
[2] C. Adra, J. Lélias, et al. Cloning of the cdna for a hematopoietic cell-specific protein related to cd20 and the beta subunit of the high-affinity ige receptor: evidence for a family of proteins with four membrane-spanning regions. Proceedings of the National Academy of Sciences, vol. 91, no. 21, p. 10178-10182, 1994. https://doi.org/10.1073/pnas.91.21.10178
[3] M. Cragg, C. Walshe, А. Иванов, & M. Glennie. The biology of cd20 and its potential as a target for mab therapy. p. 140-174, 2004. https://doi.org/10.1159/000082102
[4] F. Förster, A. Singla, S. Arora, R. Schmidt, & R. Jacobs. Cd20+ t cell numbers are decreased in untreated hiv-1 patients and recover after haart. Immunology Letters, vol. 146, no. 1-2, p. 74-78, 2012. https://doi.org/10.1016/j.imlet.2012.05.004
[5] H. Li, L. Ayer, J. Lytton, & J. Deans. Store-operated cation entry mediated by cd20 in membrane rafts. Journal of Biological Chemistry, vol. 278, no. 43, p. 42427-42434, 2003. https://doi.org/10.1074/jbc.m308802200
[6] M. Kanzaki, L. Nie, H. Shibata, & I. Kojima. Activation of a calcium-permeable cation channel cd20 expressed in balb/c 3t3 cells by insulin-like growth factor-i. Journal of Biological Chemistry, vol. 272, no. 8, p. 4964-4969, 1997. https://doi.org/10.1074/jbc.272.8.4964
[7] K. Kläsener, J. Jellusova, et al. Cd20 as a gatekeeper of the resting state of human b cells. Proceedings of the National Academy of Sciences, vol. 118, no. 7, 2021. https://doi.org/10.1073/pnas.2021342118
[8] K. Yoshinaga, M. Araki, et al. Low‐dose rituximab induction therapy is effective in immunological high‐risk renal transplantation without increasing cytomegalovirus infection. International Journal of Urology, vol. 27, no. 12, p. 1136-1142, 2020. https://doi.org/10.1111/iju.14382
[9] J. Teeling, W. Mackus, et al. The biological activity of human cd20 monoclonal antibodies is linked to unique epitopes on cd20. The Journal of Immunology, vol. 177, no. 1, p. 362-371, 2006. https://doi.org/10.4049/jimmunol.177.1.362
[10] E. Wilk, T. Witte, et al. Depletion of functionally active cd20+ t cells by rituximab treatment. Arthritis & Rheumatism, vol. 60, no. 12, p. 3563-3571, 2009. https://doi.org/10.1002/art.24998
[11] M. Cragg, S. Morgan, et al. Complement-mediated lysis by anti-cd20 mab correlates with segregation into lipid rafts. Blood, vol. 101, no. 3, p. 1045-1052, 2003. https://doi.org/10.1182/blood-2002-06-1761
[12] M. Weber, T. Prod’homme, et al. B‐cell activation influences t‐cell polarization and outcome of anti‐cd20 b‐cell depletion in central nervous system autoimmunity. Annals of Neurology, vol. 68, no. 3, p. 369-383, 2010. https://doi.org/10.1002/ana.22081
[13] W. Sun, N. Zhang, Y. Zhang, Z. Shao, L. Gong, & W. Wei. Immunophenotypes and clinical features of lymphocytes in the labial gland of primary sjogren's syndrome patients. Journal of Clinical Laboratory Analysis, vol. 32, no. 9, 2018. https://doi.org/10.1002/jcla.22585
[14] A. Pröbstel and S. Hauser. Multiple sclerosis: b cells take center stage. Journal of Neuro-Ophthalmology, vol. 38, no. 2, p. 251-258, 2018. https://doi.org/10.1097/wno.0000000000000642

Customer Reviews and Q&A

■ Customer Reviews

Average Rating:

4.5 - 2 reviews

Submit a Review here

Applications : Antigen

Review: I used the CSB-MP015007HU protein for an ELISA experiment, and the EC50 was measured to be 3.628-5.735 ng/ml, indicating good protein activity. The effect of flow cytometric analysis is also very good, with good repeatability and stable results. Product procurement is convenient and cost-effective.

By Anonymous

Applications : Binding assay/Protein-protein interaction

Review: After receiving the product, we conducted an ELISA experiment with the anti-CD20 (MS4A1) antibody, and the EC50 was 3.628-5.735 ng/ml, showing good binding activity. CD20 (MS4A1) has four times transmembrane domains, I have contacted many companies, but they can\'t express it successfully. CUSABIO expresses full-length proteins and has complete biological activity, which is very powerful!

By Anonymous

Read more reviews >>

■ Q&A

Why does the CD20 protein is almost invisible in the tube?

All CUSABIO proteins don’t contain carrier protein or other additives, such as bovine serum albumin (BSA), human serum albumin (HSA), and sucrose. When freeze-drying the lowest salt content solution, it often does not form a white grid structure, but a trace amount of protein deposits within the tube, forming a thin transparent or invisible protein layer.

Tips: Before opening the lid, we recommend centrifuging the tube in a small centrifuge for 20-30 seconds to aggregate the protein attached to the inside wall or cap of the tube to the bottom of the tube. Our quality control steps ensure that the amount of protein contained in each tube is accurate. Although sometimes you can’t see the protein powder, the protein content in the tube is still very accurate.

Does this CD20 protein soluble?

Yes, it is. We offer five expression systems: E. coli, Yeast, Baculovirus, Mammalian cell, and Cell-Free (in vitro E.coli). Among them, yeast only has supernatant expression, and the protein expressed in the supernatant must be a soluble protein.
The E. coli, Baculovirus, Mammalian cell, and Cell-Free (in vitro E.coli) have both supernatant expression and inclusion body expression. As long as the protein is expressed in the supernatant, it must be soluble. If it is expressed in the inclusion body, we will also take a variety of methods to refold it and finally ensure that all the proteins we provide are soluble.

Why should we add the protective agent to the protein solution before lyophilization? What's the general protective agent? Which kind of protective agent do you usually add?

The protective agent is used in the process of freeze-drying and storage to protect the protein.
Commonly used protective agents or stabilizers include saccharides, polyols, polymers, surfactants, some proteins, and amino acids, etc. We usually add 6% (mass ratio by volume) of trehalose as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure and the extension and aggregation of proteins during freeze-drying process. Mannitol is also a universal applied lyoprotectant and filler, which can reduce the aggregation of certain proteins after lyophilization.

Tips: For the majority of proteins, they can be only stored at 4 ℃ for a short term (about a week) after being resuspended. If you want long-term preservation, they should be formulated as a diluent (which must contain a carrier protein, such as 0.1% BSA, 5% HSA, or 10% FBS), and then repackaged and frozen at -20℃ or -80℃. Be sure to avoid repeated freezing and thawing. Because each freezing and thawing cycle will cause part of the protein inactivation.

Is the CD20 protein free of animal components?

Yes, it is. We guarantee that all proteins produced by CUSABIO are 100% animal-free, as we do not use any animal components in our raw materials and no animal components are added during the production process. Serum-free media is also used in the expression of our mammalian proteins. We can provide a declaration of no animal component if it is required.

Is this protein cell-component-free?

The protein expressed in the body, regardless of the system, is expressed by cell, and the cell expression can be divided into intracellular expression and secretory expression.
The E. coli system only has intracellular expression and needs to be broken, so the cell components are relatively more secreted than other systems.
Yeast, Baculovirus, and Mammalian cell systems can be expressed both in the cell and in the secretory expression, and the secreted expression of the protein component remains relatively less intracellular.
In vitro expression means that cell-free and the E. coli cell extract is also added, so that the cell component remains.

Therefore, no matter which expression system and which way the protein is expressed, there will be residual cell components, but we finally use affinity chromatography to purify. In theory, the residual of the cell components will be very small, but 100% of no residue cannot be guaranteed. (Nor does any companies dare to guarantee).

Can you offer aseptic manufacture processing?

Yes, we can offer an aseptic processing service and it is free of charge, but you should remark this information when placing the order. We've performed aseptic processing for liquid protein before lyophilization, but there may exist contamination during lyophilization process. To clarify, lyophilized proteins can’t guarantee aseptic processing for the whole manufacture process.

Can you remove the tag?

Not all protein tags can be removed as some proteins will be very unstable after tag removal. Please contact us in advance if you need to remove the tag which takes 2-3 business days. If we succeed in removing the tag, we will charge for extra cost for it. If we fail in removing the tag, we won't charge for any extra cost and remark this information in the datasheet as follows "Note: The laboratory determined that the tag on your protein could not be removed with standard laboratory procedures. Your protein is being supplied with the tag intact."

What is the concentration range of the protein? How do you determine the quantity of it?

The protein concentration of each batch won't be exactly the same but we could guarantee 0.1-5.0 mg/mL concentration for our expression system. If you have a special requirement for protein concentration, please contact us in advance.

There are three methods of protein concentration detection: bradford method, BCA method, A280 method. Each of these three methods has interference buffer components. According to the composition of buffer, the bradford method is the most popular with laboratories including ours, and the concentration detection range is 0.1-5 mg/mL. We also use BCA method in times.

Target Background

Function

B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR.

Gene References into Functions

Our study found that a small subset of papillary thyroid carcinomas (<10%, mainly of classic variant) exhibited aberrant membranous expression of CD20 PMID: 29079175
Our results support the fact that CD200 can be added to routine Chronic lymphoproliferative disorders panel as it is useful in subcategorizing them. However, inclusion of CD20 ABC to routine panel does not seem plausible but may be done for difficult diagnostic cases or where anti-CD20 therapy is planned. PMID: 29567884
showed here that 3' UTR NOTCH1 mutations are associated with low CD20 expression and with relative resistance to anti-CD20 immunotherapy in vitro PMID: 28550186
We conclude that the relationship between complement-regulatory proteins CFHR1 and CFHR3 and response to anti-CD20 mAb therapy varies based on the specific anti-CD20 mAb used. PMID: 27528699
Limiting the antibody-induced induction of immunosuppressive reactive oxygen species may improve the anti-leukemic efficacy of anti-CD20 therapy in chronic lymphocytic leukemia. PMID: 27097113
Case Report: primary cutaneous T-cell lymphoma with aberrant CD20 expression. PMID: 27840885
Data suggest that insulitis (destruction of pancreatic beta-cells and their ability to produce/secrete insulin) occurs in two distinct profiles in type 1 diabetes; these differ in proportion of CD20-positive B-lymphocytes (relative to CD4-positive T-lymphocytes) present within the infiltrate; greater infiltration of CD20-positive B-lymphocytes leads to more aggressive disease progression. PMID: 26858360
PZ-DHA also arrested MDA-MB-231 cell division at the G2/M phase and down-regulated expression of cyclin B1 and cyclin-dependent kinase 1 (CDK1) PMID: 27535497
there is a high CD23a/CD23b ratio of chronic lymphocytic leukemia cells, which demonstrates that in a subset of CLL cases, low CD23 expression together with high CD20 and CD38 expressions may serve as a surrogate for trisomy 12 PMID: 26119874
IL-17-producing pathogenic T lymphocytes co-express CD20 in primary Sjogren's syndrome patients. PMID: 26814615
Studies indicate that CD20 antigen expression is absent in a variety of diffuse large B cell lymphomas (DLBCLs), including plasmablastic lymphoma, primary effusion lymphoma, anaplastic lymphoma, kinase-positive DLBCL, and large B cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease. PMID: 26459310
lipid formulations based on a polyplex or lipoplex backbone additionally equipped with anti-CD20 antibodies are promising non-viral vectors for specific oligonucleotide transfer into human tumor cells. PMID: 26585505
The ABC values obtained for CD20 expression levels using PE, APC, or PerCP Cy5.5 are consistent over the five different instrument platforms for any given apparently healthy donor independent of the fluorochrome used PMID: 26013593
Data indicate that Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) patients who presented with cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) deletion showed a higher rate of CD20 antigen expression. PMID: 27090891
the findings demonstrate that treatment with anti-CD20-hIFNalpha reverses resistance of B-NHL PMID: 26398317
Case Report: aberrant CD20 expression by skin-infiltrating T cells using multispectral imaging. PMID: 26381030
Microenvironment CD20 + cells seem to play a favorable prognostic role in classical Hodgkin Lymphoma. Depletion of CD20 + cells together with an increase of TAMs identifies a group of patients with high-risk disease. PMID: 25098425
In conclusion, SNPs of CD20 were not high risk factors of DLBCL, but the T allele of rs2070770 was a potential indicator of superior survival. PMID: 24898664
Characterize premature human NK/T-cell lymphoma cell line with expression of the B-cell marker CD20. PMID: 26299072
Data indicate that CD20 antigen downregulation relies on transcriptional mechanisms in SRC family kinases (SFKs)-dependent transcriptional regulation of CD20. PMID: 25517315
This study identified a novel D393-CD20-derived MHC Class II restricted epitopes that bind various HLA-DR alleles. IFN-gamma-producing D393-CD20 specific CD4 T cell responses were detected in blood lymphocytes from lymphoma patients and D393-CD20 specific CD4 Th1 clones were able to recognize both lymphoma cell lines and autologous lymphoma cells and to induce their apoptosis. PMID: 25449106
Letter/Review: Liver transplant recipients developing CD20-positive lymphoproliferative lesions are significantly older at time of transplantation. PMID: 25394454
CD20 in multiple myeloma without the t(11;14) may have a role in poor prognosis and aberrant expression of Wnt signaling PMID: 24408089
in two cases of mycosis fungoides, CD20 was expressed by a significant population of the neoplastic T-cells, but these T-cells lacked expression of other B-cell markers, including CD79a, CD19 and PAX5. PMID: 24467775
Data indicate that depletion of CD20-expressing T cells may also contribute to the therapeutic effect of rituximab (RTX). PMID: 24928997
Significantly lower rates of CD20 B cells were found in women with placental malaria infections compared with those without such infections. Neither placental malaria infection nor CD20 are associated with low birth weight. PMID: 24245949
Expansion aggregation of CD20+ B cells, HLA-DR expression and arteriolar hyaline thickening influence the outcome of acute cellular rejection in renal allograft. PMID: 23428174
Patients whose percentage of CD20 antigen was above 60.3% had longer treatment-free survival. PMID: 23659384
CD20 protein was aberrantly expressed in T-mycosis fungoides lesions PMID: 24145652
MS4A1/CD20 is responsible for TGF-beta-induced apoptosis of B-cell lymphoma cells. Moreover, downregulation of MS4A1/CD20 by TGF-beta attenuated the effects of the monoclonal anti-MS4A1/CD20 antibody, rituximab, on Ramos cells. PMID: 22665052
Anti-hCD20 IgE antibodies have in vitro cytotoxic activity. PMID: 22692757
Case Report: CD20-positive NK/T-cell lymphoma with an indolent clinical course. PMID: 23031227
CD20 antigen is not expressed in cancer stem cells in multiple myeloma. PMID: 22315496
CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value. PMID: 22664043
Data indicate that the bridging of CD20 antigen and FcgammaRIIIa is an essential interaction for the initiation of antibody dependent cell-mediated cytotoxicity (ADCC) activity and assay. PMID: 22914441
CD20-positive posttransplant lymphoproliferative disorder lesions in kidney transplant patients are significantly more likely to develop early after transplant and represent an inferior outcome. PMID: 22758374
Data show that in the blood of rheumatoid arthritis (RA) patients, a greater proportion of Th17 cells are of a CD20+ phenotype compared to healthy individuals, suggesting these cells may represent an additional target for anti-CD20 therapies. PMID: 22171710
Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity PMID: 22843692
Dsta show that differential expression of MS4A1 is a stromal signal of uncertain significance, and an example of the rationale for tumor cell enrichment in preparation for gene expression studies to identify markers of particular tumor phenotypes. PMID: 22514692
Report disappointing results after long term treatment of lupus nephritis with anti-CD20 antibody rituximab. PMID: 21258801
B-cell depletion induces transient aggressive behavior in BDC2.5 diabetogenic T cells and reduction in regulatory T (Treg) cell number and function during the B-cell depletion period. PMID: 22490442
Defects in CD20/ B-cell receptors signalosome conformation might predispose to the spectrum of common variable immunodeficiency disorders. PMID: 22130422
Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. PMID: 22517865
Results suggest for the clinical utility of CD20-specific T cells in B cell malignancies. PMID: 21630262
Case Report: obtained good results in 2 high-titer ABO-incompatible living donor kidney transplantation using anti-CD20 and anti-CD25 antibodies without splenectomy, in conjunction with a calcineurin inhibitor plus mycophenolate mofetil or mizoribine. PMID: 21839272
Using protein tomography, different CD20 complexes were found to be associated with the 2 antibodies, and confocal microscopy showed different membrane compartmentalization of these subpopulations of the cellular CD20 pool. PMID: 21444918
The neoplastic epithelial cells in cases of type A and type AB thymoma, as well as few cases of type B1 and B2 thymoma, express CD20. PMID: 21092589
Adoptively T cells transduced anti-CD20scFvFc/CD28/CD3zeta gene mediates enhanced anti-tumor activities against CD20 positive tumor cells, suggesting a potential of gene-based immunotherapy for non-Hodgkin lymphoma. PMID: 20815894
Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. PMID: 20674973
CD20 immunoexpresion in early rheumatoid arthritis synovium. PMID: 20191119

Hide All

Involvement in disease

Immunodeficiency, common variable, 5 (CVID5)

Subcellular Location

Cell membrane; Multi-pass membrane protein. Cell membrane; Lipid-anchor.

Protein Families

MS4A family

Tissue Specificity

Expressed on B-cells.

Database Links

HGNC: 7315

OMIM: 112210

KEGG: hsa:931

STRING: 9606.ENSP00000314620

UniGene: Hs.712553

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
If CAPTCHA verification fails, click to refresh the CAPTCHA and try again.

Code	CSB-MP015007HU
MSDS	MSDS Datasheet
Size	$570
	Order now
Image	Western Blot CSB-MP015007HU is detected by Mouse anti-6*His monoclonal antibody. Activity Measured by its binding ability in a functional ELISA. Immobilized human CD20 at 2 μg/ml can bind Anti-CD20 recombinant antibody (CSB-RA015007A1HU), the EC₅₀ is 3.243-7.085 ng/mL. Biological Activity Assay The presence of VLP-like structures was confirmed by TEM Biological Activity Assay Based on the SEQUEST from database of Mammalian Cell host and target protein, the LC-MS/MS Analysis result of CSB-MP015007HU could indicate that this peptide derived from Mammalian Cell-expressed Homo sapiens (Human) CD20. Based on the SEQUEST from database of Mammalian Cell host and target protein, the LC-MS/MS Analysis result of CSB-MP015007HU could indicate that this peptide derived from Mammalian Cell-expressed Homo sapiens (Human) CD20. The purity of VLPs was greater than 90% as determined by SEC-HPLC
Have Questions?	Leave a Message or Start an on-line Chat

Recombinant Human B-lymphocyte antigen CD20 (MS4A1)-VLPs (Active)

Product Details

Related Products

Customer Reviews and Q&A

Target Background

×CloseMessage